What is known about the subject  Various prednisolone formulations are frequently used to treat asthma-like symptoms in children, the potential differences in bioequivalence between these formulations have never been examined.  Pharmacokinetic studies have traditionally been burdensome for the paediatric population due to numerous blood samples.  It is important to study the acceptability of paediatric formulations, since manipulating medicine or introducing different formulations may diminish or enhance tolerability.
What this study hopes to add
 Paediatric bioequivalence data on prednisolone oral solution, crushed tablets and oro-dispersible tablets compared to whole tablets.  Prednisolone concentration data is collected using saliva samples, validated with plasma samples if the patient has an intravenous access for clinical purposes.
 Acceptability data on different prednisolone formulations using a modified Wong Baker face scale. 
Abstract Introduction
One in three Danish children under three years of age experience asthma-like symptoms and one third will later be diagnosed with asthma. Oral prednisolone is used in various formulations to treat acute asthma. However, the potential differences in bioequivalence between these formulations have never been examined in children despite interchangeable use in clinical practice.
Methods and analysis
An open-label, randomised two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. The included patients (6 months to 11 years of age) are admitted to the Department of Paediatric-and Adolescent Medicine Nordsjaellands University Hospital, Hillerød with asthma or asthma-like symptoms. The primary objective is to assess the bioequivalence between different prednisolone formulations herein AUC, Cmax and Tmax using saliva samples. The secondary objectives are to evaluate tolerability (5-point face scale), adverse events and severity of the disease. If the patient has an intravenous access for other purposes the saliva samples will be validated with plasma samples. A total of 66 evaluable patients are needed according to European Medicines Agency (EMA) Guideline on bioequivalence.
Ethics and dissemination
Traditional pharmacokinetic trials are burdensome due to the extent of blood samples, necessary to capture the time-dependant drug profile. Saliva sampling are far more acceptable for paediatric patients, in addition this trial adheres to standard dosing strategies. No additional venepunctures are performed.
Registration details
The Danish Medicines Agency EudraCT: 2017-003590-33, The Ethics Committee case no: H-17027252, and the Danish Data Protection Agency: BFH-2017-103, I-Suite no.: 05935. One in three Danish children under three years of age experience asthma-like symptoms and one third will later be diagnosed with asthma [1] . Therapeutic management of acute asthma-like symptoms in infants and children has been repeatedly discussed [2] . Oral glucocorticoids are frequently added to inhaled beta-2agonist if the patient does not respond to the initial treatment. However, no therapeutic interval exists for glucocorticoids and no clinical biomarker has been deveopled to asses efficacy [3] . Furthermore, in Denmark, only intravenous (i.v.) formulations and prednisolone or hydrocortisone tablets are licensed for patients < 18 years of age [4] . Infants and children who are unable or unwilling to swallow a tablet or where dosing is based on body weight are urged to use either an extemporaneous oral liquid formulation, crushed or split tablets. Splitting tablets may lead to dose inaccuracy and in one study crushing hydrocortisone tablets lead to therapeutic failure [5] . Extemporaneous formulations are not subject to randomised controlled trials as licensed formulations and bioequivalence (BE) are not determined between different formulations with the same active ingredience [5, 6] . Moreover, the paediatric population is a heterogeneous group of patients ranging from premature neonates to adolescents. The wide physical and developmental differences influence both pharmacokinetic (PK) and pharmacodynamic parameters. These issues are generally poorly studied [7] . BE studies compare both the rate (the time to Cmax =Tmax) and extent of absorption (area under the concentration time curve (AUC) of various drug formulations. Regulatory guidelines on BE state that two treatments are not different from one another if the 90% confidence interval of the ratio of a logtransformed exposure measure (AUC and/or Cmax) falls within the range of 80-125% [8] .
To date one bioequivalence study with prednisolone have been performed in healthy adults [9] . examined AUC, Tmax and Cmax of five commercially oral prednisone tablets compared with one reference solution in 18 healthy adults [9] . No statistically significant differences were found between the tablets. Non-significant variations were seen between the solution and tablets except for Tmax, which was 0.53 and 1.2-1.7 hours, respectably [9] . A bioavailability study from compared liquid prednisone, prednisone tablet and i.v. prednisolone [10] , and found that the AUC for liquid and tablet were significantly different [10] . No studies have been performed in a target patient population, taking into consideration factors such as co-morbidities, co-medication and physiological factors including first pass metabolism, gastric pH and bacterial flora, highly relevant in infants and children. However, traditional PK trials are burdensome due to the extent of blood samples, necessary to capture the time-dependant drug profile. New non-invasive methods such as saliva sampling are far more acceptable for paediatric patients. In a recent adult population PK study free prednisolone concentrations correlated well with salivary concentrations [11] . The same study set-up were later applied in a population pharmacokinetic model in paediatric patients (N=104) with nephrotic syndrome [12] . None of the studies included more than one formulation.
The importance to study the acceptability of paediatric formulations has recently been endorsed since manipulating medicine or introducing different formulations may diminish or enhance tolerability [13] . Acceptability of medicines influence adherence to therapeutic regimens and outcomes. No validated method to access acceptability of paediatric medicine exists and many different scales have been used most commonly hedonic face scales or VAS scales [13] . Lucas-Bouwman et al (2000) investigated the acceptability of prednisolone oral solution and crushed tablets using VAS taste scale.The oral solution
obtained the best score and no vomiting was observed in the oral solution treatment group compared to 23% in the other group [14] . Aljebab et al (2018) showed that dexamethasone elixir was more palatable than prednisolone tablets, soluble tablets and syrup using af 5-point hedonic face scale in children below 12 years of age in the UK and Saudi Arabia [15] . Prednisolone syrup and soluble tablets caused less vomiting than tablets [15] .
Objectives
We aim to investigate the bioeqvalence of different prednisolone formulations in three different agegroups and secondary to investigate the tolerability, adverse events, severity of the disease and validation of saliva samples, Table 1 .
Methods and analysis
A single centre randomised open-label two-treatment cross-over design. Children with asthma-like symptoms admitted to the Department of Paediatric and Adolescent Medicine, Nordsjaellands University Hospital, Hillerød are eligible for inclusion.
Population
Eligibility criteria are described in Table 2 . Patients are stratified by age in accordance with EMA guidelines into three groups i.e. 6-23 months, 2-5 yrs. and 6-11 yrs. [16] . Two different formulations of prednisolone as 1 mg/kg/day will be administered to each participant for two consecutive days, Figure 1 . A control group of school children age 6 to 11 years will receive whole tablets. In total, four different formulations will be investigated, see Figure 1 . All trial medicine is labelled, packed and distributed by the Regional Pharmacy in accordance with GMP Annex 13 (2010) [17] , except the high-strength oral prednisolone solution 20 mg/ml which is "ward medicine" and does not require special labelling. A separate accountancy is kept for each formulation of prednisolone.
Patient involvement
Patients were not directly involved in the design of this study.
Saliva samples
The primary and secondary outcomes are assessed at pre-defined time points shown in Table 3 and Figure  1 . For saliva sampling two sampling groups, A and B, exists, Figure 1 , calculated on the basis of a previous study [12] . Each child will follow the same time schedule for both doses. The samples will be collected using the SalivaBio Children's Swab and the SalivaBio Oral Swab (exclusively from Salimetrics®, State College, PA), synthetic swabs specifically designed to improve volume collection and increase participant compliance. Saliva will be removed from the swabs by centrifuge (15 minutes at 2500 rpm) and stored in cryovials at -20 ᵒC for maximum two weeks and hereafter at -80°C until analysis. Concentrations of prednisolone and its inactive metabolite prednisone will be determined by liquid chromatography with mass-spectrometric detection. The assay is validated according to the EMA guideline "Guideline on bioanalytical method validation" (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**Committee for Medicinal Products for Human Use (CHMP)). Analyses are performed in accordance with ISO 15189. Concentrations will be determined in 10 microliter saliva or plasma. In the latter case both total and unbound concentrations will be determined. The lower limit of quantification is 2 ng/ml for both compounds. Saliva samples are non-invasive samples and are considered a painless low risk procedure [16] . Saliva sampling of prednisolone and subsequent analysis has recently been performed in children with median 4,6 years of age using Salivette® equipment [12] . As this trial includes children from 6 months of age we chose the Salimetrics® equipment. If any child has a cubital i.v. access during inclusion in the trial, additional blood-samples will be taken time equivalent to assess plasma prednisolone to validate the saliva samples. No additional venepunctures will be made.
Sample size
The number of subjects required for a BE study depends on the expected deviation between formulations [18] . Because of limited data on prednisolone pharmacokinetics and BE of different formulations, sample size calculation is not feasible. In accordance with the EMA guideline on the investigation of BE [8] the number of subjects to be included in a study should preferably be based on sample size calculations and not be less than 12. To account for drop-outs 14 patients were allocated to each formulation in the threedifferent age-groups and the control group (a total of 77 patients), Figure 1 . The optimal number of participants is 66 evaluable patients.
Randomisation
The participants are randomised in the REDCap software. The REDCap software is mandatory to use in investigator-initiated research in the Capital Region in Denmark. The randomisation list is uploaded in REDCap and is blinded to everyone except a third person, who generates the list and has no other role in the trial. The participants are age stratified and will be block randomised to ensure an equal amount in each subgroup, Figure 1 . The child will receive a REDCap generated ID-number including a combination of letters describing the formulations to be given. Administration of prednisolone is done open-label by the project staff or paediatric nurses.
Statistical methods
The time dependant prednisolone concentrations in saliva will be analysed using PK modelling [12] . The person responsible for the statistical analysis of saliva samples will be blinded to the formulations given. Descriptive statistics are used to describe demographic data. BE will be determined if the ratio of the test and reference of AUC and Cmax is within the 90% confidence intervals with an accepted interval of 80.00-125.00% [8] using ANOVA or t-test. All patients who fulfils the eligibility criteria and have had at least one saliva sample taken will be analysed for demographic and baseline data. In the pharmacokinetic modelling all saliva samples will be included. If any pre-dose concentration is more than 5% of Cmax, this will be reported and handled appropriately in the final analysis.
Ethics and dissemination
Before prednisolone treatment is initiated a patient-information sheet is given to eligible patients and the trial is explained to their parents. Parents will have a minimum of 15 minutes to consider the consent, because treatment should not be unnecessary delayed. Informed consent will be granted by parents or legal guardian, as all children are below 15 years of age. If one of the parents is not present a written authority can be used. The consent process will be conducted by an investigator with training and experience with minors. The collected material is considered a research biobank. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Safety
Despite a large therapeutic index, it is important that all glucocorticoids are administered in the lowest effective dose as possible, since a considerable number of dose dependent adverse drugs reactions (ADR´s) are well described [4] . A recent review found that the most frequent ADR´s associated with short course oral corticosteroids (<14 days) in children were vomiting, changes in behavoiur and sleep disturbances with incidence rates of 5.4%, 4.7% and 4.3% respectively. Increased susceptability to infection were one of the serious ADR´s ocurring in up to 1% of the children [19] .
Trial limitations
Alterations have been made in this trial compared to a classic BE trial to adapt to the relevant population. This trial is a single dose study performed during admission with a theoretical wash out period of 24 h, as prednisolone is dosed once daily. The half-life of prednisolone is 2.5±0.5 h [20, 21] and 24 h should be enough time to ensure drug concentrations below quantification. However, as a precaution pre-dose samples are collected if prednisolone has been administered the day before inclusion. The saliva samples will be measured in 11 or 12 hours respectively, which will be within 5 half-lives for many patients. Late night samples will be more difficult to collect if the participants are asleep and some might not be collected due to patient and parent preferences.
The reference product in this trial is whole tablets, since i.v. glucocorticoids are mainly used for severe asthma. The effect of fasting and fed are not within the scope of this trial since no effect on bioavailability was found in prednisolone whole tablets [4] . To avoid prednisolone left overs in the mouth all children will be given water after administration of trial medicine. There can be differences in which the hedonic face scale is presented to the child and this can be of some limitation, Figure 2 . Only 2-5 persons will include participants in this trial, minimising the variability.
We expect to have some dropouts due to 1) non-compliance with the formulations and 2) due to earlier than expected discharge. In the control group with whole tablets data suggest that about 91% of 6 year old children can swallow a 7 mm tablet [13] . The whole tablets are 8 mm (5 mg) and 10 mm (25 mg) but with break lines. We chose to include two strengths of prednisolone oral solution, to make sure the volumes were measurable and acceptable [13] . Dropouts and inclusion only during daytime could give some recruitment bias; however, as this is primarily a pharmacokinetic trial, we do not expect this to influence the results. This trial in only performed at one centre which can limit the generalisability but will enhance the consistency.
Trial registration
This trial is an investigator-initiated trial from the Department of Clinical Pharmacology, Bispebjerg Hospital and the Department of Paediatric and Adolescent Medicine, Nordsjaellands Hospital, Hillerød. The trial is approved by the Danish Medicines Agency EudraCT: 2017-003590-33, the Ethics Committee case no: H-17027252 and the Danish Data Protection Agency: BFH-2017-103, I-Suite no.: 05935. The trial is monitored by the GCP-unit Copenhagen University. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Figure 2
Modified Wong Baker face scale to access tolerability of trial medicine. Self-reported tolerability of the medicine is collected from children older than 6 years of age. The options A to E is read aloud neutrally to the child. For children below 6 years of age a parent is asked to evaluate the tolerability. Vomiting is registered separately but is included in the face scale as F. Primary and secondary objectives and outcomes in the POP child trial Table 1 Objectives and outcomes.
Primary objective Primary outcome To investigate the bioequivalence of different prednisolone formulations i.e. crushed tablets, oral solution, and oro-dipersible tablets to characterise their bioequivalence compared to standard whole tablets (controls). Herein compare the AUC, Cmax and Tmax Concentration-time data on prednisolone concentration measured in saliva to determine AUC, Tmax and Cmax.
Secondary objective
Secondary outcome 1. Acceptability of different formulations assessed by patient preferences and number of attempts 2. Adverse events. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 2 In-and exclusion criteria for the POP child trial Table 2 Inclusion-and exclusion criteria for the POP Child trial.
Inclusion criteria
Exclusion criteria Children from 6 months to 11 years of age, both gender, all ethnicities.
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What this study hopes to add
 Acceptability data on different prednisolone formulations using a modified Wong Baker face scale. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Abstract Introduction
Methods and analysis
Ethics and dissemination
Traditional pharmacokinetic trials are burdensome due to the extent of blood samples necessary to capture the time-dependant drug profile. Saliva sampling are far more acceptable for paediatric patients. In addition, this trial adheres to standard dosing strategies. No additional venepunctures are performed, and no additional prednisolone doses are administered. Guidelines for paediatric bioequivalence trials are warranted.
Registration details
The Danish Medicines Agency EudraCT: 2017-003590-33, The Ethics Committee case no: H-17027252, and the Danish Data Protection Agency: BFH-2017-103, I-Suite no.: 05935. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Introduction
One in three Danish children under three years of age experience asthma-like symptoms and one third will later be diagnosed with asthma [1] . Therapeutic management of acute asthma-like symptoms in infants and children has been repeatedly discussed [2] . Oral glucocorticoids are frequently added to inhaled beta-2agonist if the patient does not respond to the initial treatment. However, no therapeutic interval exists for glucocorticoids and no clinical biomarker has been deveopled to asses efficacy [3] . Furthermore, in Denmark, only intravenous (i.v.) formulations and prednisolone or hydrocortisone tablets are licensed for patients < 18 years of age [4] . Infants and children who are unable or unwilling to swallow a tablet or where dosing is based on body weight are urged to use either an extemporaneous oral liquid formulation, crushed or split tablets. Splitting tablets may lead to dose inaccuracy and in one study crushing hydrocortisone tablets lead to therapeutic failure [5] . Extemporaneous formulations are not subject to randomised controlled trials as licensed formulations and bioequivalence (BE) are not determined between different formulations with the same active ingredience [5, 6] . Moreover, the paediatric population is a heterogeneous group of patients ranging from premature neonates to adolescents. The wide physical and developmental differences influence both pharmacokinetic (PK) and pharmacodynamic parameters. These issues are generally poorly studied [7] . BE studies compare both the rate (the time to Cmax =Tmax) and extent of absorption (area under the concentration time curve (AUC) of various drug formulations. Regulatory guidelines on BE state that two treatments are not different from one another if the 90% confidence interval of the ratio of a logtransformed exposure measure (AUC and/or Cmax) falls within the range of 80-125% [8] .
To date one bioequivalence study with prednisolone have been performed in healthy adults [9] . examined AUC, Tmax and Cmax of five commercially oral prednisone tablets compared with one reference solution in 18 healthy adults [9] . No statistically significant differences were found between the tablets. Non-significant variations were seen between the solution and tablets except for Tmax, which was 0.53 and 1.2-1.7 hours, respectably [9] . A bioavailability study from Georgitis et al (1982) compared liquid prednisone, prednisone tablet and i.v. prednisolone [10] , and found that the AUC for liquid and tablet were significantly different [10] . No studies have been performed in a target patient population, taking into consideration factors such as co-morbidities, co-medication and physiological factors including first pass metabolism, gastric pH and bacterial flora, highly relevant in infants and children. However, traditional PK trials are burdensome due to the extent of blood samples, necessary to capture the time-dependant drug profile. New non-invasive methods such as saliva sampling are far more acceptable for paediatric patients. In a recent adult population PK study free prednisolone concentrations correlated well with salivary concentrations [11] . The same study set-up were later applied in a population pharmacokinetic model in paediatric patients (N=104) with nephrotic syndrome [12] . None of the studies included more than one formulation.
The importance to study the acceptability of paediatric formulations has recently been endorsed since manipulating medicine or introducing different formulations may diminish or enhance tolerability [13] . Acceptability of medicines influence adherence to therapeutic regimens and outcomes. No validated method to access acceptability of paediatric medicine exists and many different scales have been used most commonly hedonic face scales or VAS scales [13] . Lucas-Bouwman et al (2000) investigated the acceptability of prednisolone oral solution and crushed tablets using VAS taste scale.The oral solution 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 obtained the best score and no vomiting was observed in the oral solution treatment group compared to 23% in the other group [14] . Aljebab et al (2018) showed that dexamethasone elixir was more palatable than prednisolone tablets, soluble tablets and syrup using af 5-point hedonic face scale in children below 12 years of age in the UK and Saudi Arabia [15] . Prednisolone syrup and soluble tablets caused less vomiting than tablets [15] .
Objectives
We aim to investigate the bioeqvalence of different prednisolone formulations in three different agegroups and secondary to investigate the tolerability, adverse events, severity of the disease and validation of saliva samples, Table 1 . 
Methods and analysis

Population
Patient involvement
Saliva samples
The primary and secondary outcomes are assessed at pre-defined time points shown in Table 3 and Figure  1 . For saliva sampling two sampling groups, A and B, exists, Figure 1 , calculated on the basis of a previous study [12] . Each child will follow the same time schedule for both doses. The samples will be collected using the SalivaBio Children's Swab and the SalivaBio Oral Swab (exclusively from Salimetrics®, State College, PA), synthetic swabs specifically designed to improve volume collection and increase participant compliance. Saliva will be removed from the swabs by centrifuge (15 minutes at 2500 rpm) and stored in cryovials at -20 ᵒC for maximum two weeks and hereafter at -80°C until analysis. Concentrations of prednisolone and its inactive metabolite prednisone will be determined by liquid chromatography with mass-spectrometric detection. The assay is validated according to the EMA guideline "Guideline on bioanalytical method validation" (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**Committee for Medicinal Products for Human Use (CHMP)). Analyses are performed in accordance with ISO 15189. Concentrations will be determined in 10 microliter saliva or plasma. In the latter case both total and unbound concentrations will be determined. The lower limit of quantification is 2 ng/ml for both compounds. Saliva samples are non-invasive samples and are considered a painless low risk procedure [16] . Saliva sampling of prednisolone and subsequent 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 analysis has recently been performed in children with median 4,6 years of age using Salivette® equipment [12] . As this trial includes children from 6 months of age we chose the Salimetrics® equipment. If any child has a cubital i.v. access during inclusion in the trial, additional blood-samples will be taken time equivalent to assess plasma prednisolone to validate the saliva samples. No additional venepunctures will be made.
Sample size
Randomisation
The participants are randomised in the REDCap software (www.project-redcap.org). The REDCap software is mandatory to use in investigator-initiated research in the Capital Region in Denmark. The randomisation list is uploaded in REDCap and is blinded to everyone except a third person, who generates the list and has no other role in the trial. The participants are age stratified and will be block randomised to ensure an equal amount in each subgroup, Figure 1 . The child will receive a REDCap generated ID-number including a combination of letters describing the formulations to be given. Administration of prednisolone is done open-label by the project staff or paediatric nurses.
Statistical methods
The AUC(0-t) and Cmax parameters will be calculated using single subject compartmental modelling. Actual time of sampling will be used in the estimation of the pharmacokinetic parameters. The assessment of bioequivalence will be based upon 90% confidence intervals for the ratio of the population geometric means (test/reference), with the null hypothesis of bioequivalence at the 5% significance level (acceptance interval of 80.00-125.00%) [8] using ANOVA or t-test. The comparison between the different age-groups will be done in a stepwise manor, initially comparing the various subpopulation, e.g. the 6-23 moth old. If these data are comparable, we will pool the data and compare to the older age groups. The oldest age group will only then serve as control group across age population. If the data do not show BE, the bioavailability data will be reported separately for each age group.
The person responsible for the statistical analysis of saliva samples will be blinded to the formulations given. Due to the limited wash-out period, a test for carry-over will be addressed by examination of the pre-treatment plasma concentrations in period 2. All patients who fulfils the eligibility criteria and have had at least one saliva sample taken will be analysed for demographic and baseline data. In the pharmacokinetic modelling all saliva samples will be included. If any pre-dose concentration is more than 5% of Cmax, this will be reported and handled appropriately in the final analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Ethics and dissemination
Before prednisolone treatment is initiated a patient-information sheet is given to eligible patients and the trial is explained to their parents. Parents will have a minimum of 15 minutes to consider the consent, because treatment should not be unnecessary delayed. Informed consent will be granted by parents or legal guardian, as all children are below 15 years of age. If one of the parents is not present a written authority can be used. The consent process will be conducted by an investigator with training and experience with minors. The collected material is considered a research biobank.
Safety
Trial limitations
Alterations have been made in this trial compared to a classic BE trial to adapt to the relevant population. There are no existing guidelines for paediatric BE trials. A guideline is warranted since paediatric BE trials must be pragmatic in order to adapt to the paediatric population and be conducted ethically. Optimally, a randomised, two/three-period, two/three-sequence single dose crossover design would be used for healthy adults. This trial is a single dose study performed during admission, limiting the possible number of doses/formulations per patient, with a theoretical wash out period of 24 h, as prednisolone is dosed once daily. The half-life of prednisolone is 2.5±0.5 h [20, 21] and 24 h should be enough time to ensure drug concentrations below quantification. However, as a precaution pre-dose samples are collected if prednisolone has been administered the day before inclusion. The saliva samples will be measured in 11 or 12 hours respectively, which will be within 5 half-lives for many patients. Late night samples will be more difficult to collect if the participants are asleep and some might not be collected due to patient and parent preferences.
We expect to have some dropouts due to 1) non-compliance with the formulations and 2) due to earlier than expected discharge. In the control group with whole tablets data suggest that about 91% of 6 year old children can swallow a 7 mm tablet [13] . The whole tablets are 8 mm (5 mg) and 10 mm (25 mg) but with break lines. We chose to include two strengths of prednisolone oral solution, to make sure the volumes were measurable and acceptable [13] . Dropouts and inclusion only during daytime could give some recruitment bias; however, as this is primarily a pharmacokinetic trial, we do not expect this to influence 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 the results. This trial in only performed at one centre which can limit the generalisability but will enhance the consistency.
Trial registration
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Figure 2
Modified Wong Baker face scale to access tolerability of trial medicine. Self-reported tolerability of the medicine is collected from children older than 6 years of age. The options A to E is read aloud neutrally to the child. For children below 6 years of age a parent is asked to evaluate the tolerability. Vomiting is registered separately but is included in the face scale as F. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 1 Primary and secondary objectives and outcomes in the POP child trial Table 1 Objectives and outcomes.
Primary objective
Primary outcome To investigate the bioequivalence of different prednisolone formulations i.e. crushed tablets, oral solution, and oro-dipersible tablets to characterise their bioequivalence compared to standard whole tablets (controls). Herein compare the AUC, Cmax and Tmax Concentration-time data on prednisolone concentration measured in saliva to determine AUC, Tmax and Cmax.
Secondary objective
Secondary outcome 1. Acceptability of different formulations assessed by patient preferences and number of attempts 2. Adverse events. 3. Modified Pulmonary Index Score (MPIS) and Paediatric Early Warning Score (PEWS) 4. Validation of the saliva samples using plasma samples.
1. Acceptability of different formulations measured by a modified Wong-Baker FACES scale, see Figure 2 2. Adverse events registration 3. MPIS and PEWS score at administration time for dose 1 and 2 4. Concentration-time data on prednisolone concentration measured in plasma to determine AUC, Tmax and Cmax 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 2 In-and exclusion criteria for the POP child trial Table 2 Inclusion-and exclusion criteria for the POP Child trial.
Inclusion criteria
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